Wall Street hasn't fully digested what currency devaluation really means for biotech stocks.

Expect a big swing in the market – up or down – in the coming month.

Important clinical trial results in Alzheimer's, cancer and Crohn's disease and a big FDA decision for Sarepta are expected before the end of the year.

I have a plethora of indicators that say we should get some sort of correction.

Trade-Ideas LLC identified Repligen (RGEN) as a weak on high relative volume candidate

Trade-Ideas LLC identified Repligen (RGEN) as a "dead cat bounce" (down big yesterday but up big today) candidate

Stocks with insider trader activity include RGEN, DVA and FLT

Trade-Ideas LLC identified Repligen (RGEN) as a new lifetime high candidate

Trade-Ideas LLC identified Repligen (RGEN) as a new lifetime high candidate

"For 2023, we again expect solid growth in our two most important measures of success: revenue and free cash flow," said CFO Jim Kavanaugh.

"I am deeply sorry for the impact to our employees and customers," said Southwest CEO Bob Jordan.

"We achieved these results while continuing to invest in broadband, our 10G network evolution, Xfinity Mobile, Peacock, and theme parks, and we also took cost actions to further our growth in the future," said CEO Brian Roberts.